Epstein-Barr Virus: Symptoms and Treatment
For immunocompetent individuals, EBV infection is self-limited and requires only supportive care; antiviral drugs are not effective and should not be used. 1, 2
Clinical Presentation
Primary Infection (Infectious Mononucleosis)
The classic triad of symptoms includes:
- Pharyngitis (often severe, diphtheroid angina)
- Cervical lymphadenopathy
- Fever (high-grade, episodic)
Additional common features 3, 4, 5:
- Profound fatigue lasting weeks to months
- Hepatosplenomegaly
- Marked lymphocytosis with atypical lymphocytes on blood smear
Critical timing: The incubation period is unusually long at approximately 6 weeks, distinguishing it from most acute viral illnesses 5. The disease typically affects adolescents and young adults (ages 15-25 years) 3.
Atypical Presentations
Be alert for prominent constitutional symptoms and extensive lymphadenopathy that may mimic lymphoma 4, 6. Always test for EBV in adults presenting with fever and lymphadenopathy to avoid unnecessary invasive investigations 6.
Diagnosis
- Heterophile antibody tests (Monospot) for rapid screening
- EBV-specific serology: IgM antibodies confirm acute infection 3
- Complete blood count showing lymphocytosis with atypical lymphocytes
- Abdominal ultrasound if hepatosplenomegaly suspected 3
Treatment Approach
Immunocompetent Patients
- Rest and hydration
- Analgesics for pain/fever
- Avoid contact sports for 3-4 weeks due to splenic rupture risk
Corticosteroids - Reserved for specific complications only 1:
- Upper airway obstruction (pharyngeal)
- Immune-mediated severe anemia
- Immune-mediated thrombocytopenia
What NOT to use:
- Antiviral drugs are ineffective against EBV in immunocompetent hosts and should not be prescribed 1, 2
- Routine corticosteroids are not indicated for uncomplicated cases 1
Immunocompromised Patients (Post-Transplant Setting)
This represents a completely different clinical scenario requiring aggressive intervention 7:
For EBV DNAemia without symptoms (Pre-emptive therapy):
- Rituximab 375 mg/m² weekly for 1-4 doses until EBV DNA negativity 7
- Reduce immunosuppression if possible (except in severe GVHD) 7
For Post-Transplant Lymphoproliferative Disorder (PTLD):
- First-line: Rituximab 375 mg/m² weekly (70% response rate) 7
- Combined with immunosuppression reduction when feasible 7
- EBV-specific cytotoxic T lymphocytes if available 7
Common Pitfalls
Do not prescribe antivirals (acyclovir, valacyclovir) for typical infectious mononucleosis - they provide no benefit 7, 1, 2
Do not use corticosteroids routinely - reserve only for life-threatening airway obstruction or severe immune-mediated cytopenias 1
Do not miss atypical presentations - extensive lymphadenopathy may mimic malignancy; obtain EBV serology before pursuing invasive biopsies 4, 6
Warn about splenic rupture risk - avoid contact sports and heavy lifting for at least 3-4 weeks
Prognosis
Recovery typically occurs without complications over weeks to months 3. Severe courses and complications are rare in immunocompetent individuals 3. The prognosis is generally excellent with conservative management 3, 1.